Business

Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection

Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection

articleBio-thera Solutions, Ltd. Class AJanuary 9, 20265/news/announcement-on-voluntary-disclosure-of-milestone-payment-received-for-signing-authorization-license-and-commercialization-agreement-with-hikma-pharmaceuticals-usa-inc-for-bat2206-ustekinumab-injection
Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection

About this update from Bio-thera Solutions, Ltd. Class A

Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Bio-thera Solutions, Ltd. Class A